Clinical Trials
Looking for a clinical trial? Please see what active studies we have and contact us!
Patient Testimonal
Lelia contracted a CDI after giving birth to her second child. Thanks to the work of Dr. Kraft and BetterGut, she was able to receive a fecal microbiome transplant that greatly improved her quality of life. Click on the video above to learn more about Lelia's experience!
PREMIX
A Pilot Study Using Fecal Microbiota Transplant in Renal Transplant Recipients to Eliminate Multidrug-Resistant Organism Colonization after Infection and Examine Gastrointestinal Carriage in a Randomized Placebo-Controlled Design
Full Study Title
Indication
Seeking those that have received a renal transplant and have a history of MDRO infection.
Research Program Study
Outpatient FMT via enema to treat multiple drug resistant organisms (MDRO's) in renal transplant patients and achieve 36 days with negative stool tests. Patients will be followed for 24 weeks (4 visits to The Emory Clinic and at least 6 phone calls). Participants are asked (but not required) to collect stool samples at 4 time points to be collected by courier from their home. Participants will be asked to keep a log of bowel movements for first few weeks and refrain from probiotics for the entirety of the study.
Adults with a history of multidrug resistant (MDR) infections
Patient Population
Clinical Program /
Mode of Treatment
Enema - FMT
SERES-016
Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides difficile Infection (RCDI)
Full Study Title
Indication
Seeking those who have had ≥ 2 lifetime confirmed episodes of CDI, inclusive of the current episode and are not presently receiving antibiotic treatment
Research Program Study
Study will involve two visits to Emory (Screening/Pre-enrollment visit and the Day 1 Dosing visit)
Treatment will consist of four pills , taken three days in a row. Dosing for Day 1 will be in clinic
Subjects will be followed for safety monitoring for 24 weeks, via monthly phone calls, to assess for adverse events of special interest (AESIs) and/or serious adverse events (SAEs)
Adults with recurrent C. difficile infection
Patient Population
Clinical Program /
Mode of Treatment
Expanded Access pill study containing firmicute spores derived from healthy donor stool
PROTECT
Bacillus velezensis DSM 33864 for reduction of the risk of recurrent Clostridioides difficile infections
Full Study Title
Indication
Seeking those with medical record documentation of second episode of CDI who are not presently receiving antibiotic therapy
Research Program Study
Treatment will consist of one pill taken each day with breakfast for eight weeks. Dosing for Day 1 will take place the morning after the Baseline visit. All supplementation will be taken in the patient’s home. Study will involve five visits. Four of these visits (Screening, Baseline, End of Supplementation and a 12 week follow-up visit) will be at Emory. The Week 4 visit will be conducted by phone. Subjects will be followed for safety monitoring for 4 weeks. There will be four stool sample collections and three blood draws in this study as well as the use of paper-based questionnaires and the use of study diary for the duration of the study.
Adults with recurrent C. difficile infection
Patient Population
Clinical Program /
Mode of Treatment
Pill - FMT